Brain Cancer

Brain and central nervous system tumors are the second most common malignancy among children and the most prevalent form of solid tumor, according to American Cancer Society data.

Survivors of childhood cancer are at risk for neurocognitive decline later in life related to the disease and treatment, a complication that may become more common as cancer treatments improve and more survivors reach adulthood.

Inspired by the death of then-Vice President Joe Biden’s son, Beau, due to glioblastoma, the NCI launched the Cancer Moonshot in 2016 with the goal of advancing cancer research and treatment.

The FDA granted orphan drug designation to LP-184 for the treatment of glioblastoma multiforme and other malignant gliomas.

The International Society of Magnetic Resonance in Medicine awarded Natalie J. Serkova, PhD, the 2021 Senior Fellow Award for her work in animal imaging for oncology research.

Young children with brain tumors experienced cognitive difficulties prior to adjuvant treatment, with those of a younger age at diagnosis and lower socioeconomic status at greatest risk, according to a study in Journal of Clinical Oncology.

The FDA granted orphan drug designation to iniparib for treatment of malignant glioma, according to the agent’s manufacturer.

Genetic alterations of ALK, including clonal mutations and amplifications, in high-risk neuroblastoma demonstrated utility as independent predictors of poorer survival, according to a study published in Journal of Clinical Oncology.

Patients with glioma who completed the 8-week GLioma Atkins-based Diet experienced “meaningful” ketonuria and significant systemic and cerebral metabolic changes, according to results from a small study published in Neurology.

The FDA granted fast track designation to berubicin for the treatment of recurrent glioblastoma multiforme, according to the agent’s manufacturer.